Vendor, Plainsboro, NJ
Atux Iskay Group LLC
UEI C7JPQ5F3UUH7, CAGE 88C46
2 awards and $355,000 obligated between February 12, 2024 and February 11, 2025, 100% under full and open competition, against 17.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $355,000 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91024C00009Definitive Contract, February 12, 2024, Full and Open Competition After Exclusion of Sources, 27 offers | NIH NCINational Institutes of Health | SBIR Concept Award - Therapeutics - Sulfonyl-Urea and Sulfonamide PP2A Activators as Mycn Amplified Neuroblastoma (Nbl) TherapeuticsNAICS 541715, PSC AN12 | $355,000 |
| 75N91023C00038Definitive Contract, September 12, 2024, Full and Open Competition After Exclusion of Sources, 7 offers | NIH NCINational Institutes of Health | SBIR Phase I Topic #446 - Development of Senotherapeutic Agents for Cancer TreatmentNAICS 541715, PSC AN12 | $0 |
- Places of performance
- New Jersey
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 6 across 2 awards